Fibrosis is a pathophysiological hallmark of cardiorenal disease. In the heart, fibrosis leads to contractile dysfunction and arrhythmias; in the kidney, it is the final common pathway for many diseases and predicts end-stage renal failure. Despite this, there are currently no specific anti-fibrotic treatments available for cardiac or renal disease. Recently and unexpectedly, IL-11 was found to be of major importance for cardio-renal fibroblast activation and fibrosis. In mouse models, IL-11 overexpression caused fibrosis of the heart and kidney while genetic deletion of \textit{Il11ra1} protected against fibrosis and preserved organ function. Neutralizing antibodies against IL-11 or IL-11RA have been developed that have anti-fibrotic activity in human fibroblasts and protect against fibrosis in murine models of disease. While IL-11 biology has been little studied and, we suggest, largely misunderstood, its autocrine activity in myo-fibroblasts appears non-redundant for fibrosis, which offers new opportunities to better understand and potentially target cardiorenal fibrosis.

**1** | **FIBROSIS: A FINAL COMMON PATHWAY UNDERLYING CARDIAC AND RENAL FAILURE**

Fibrosis occurs in response to tissue injury. While this may be adaptive in the short term, prolonged or uncontrolled fibrogenesis leads to parenchymal disruption and loss of tissue function, eventually resulting in organ failure (Rockey, Bell, & Hill, 2015a). Two organs notably affected by fibrosis are the heart and the kidney, where the resulting cardiac and renal failure are significant contributors to global morbidity and mortality (Rockey et al., 2015a; Rosenbloom, Macarak, Piera-Velazquez, & Jimenez, 2017).

Myocardial fibrosis contributes to both systolic and, particularly, diastolic ventricular impairment, resulting in increased myocardial stiffness, impaired relaxation and eventually contractile dysfunction (González, Schelbert, Diez, & Butler, 2018; Moreo et al., 2009). A collagenous scar can also slow conduction, form micro-reentrant circuits and produce triggered activity (Rockey et al., 2015a) to promote malignant ventricular arrhythmias (Chen et al., 2015; Iles et al., 2011). Consequently, the presence of ventricular fibrosis is a major predictor of sudden cardiac death (Gulati et al., 2013; Halliday et al., 2017; Musa et al., 2018). Fibrosis is also a pathophysiological hallmark of atrial fibrillation (Gal & Marrouche, 2017; Kottkamp, 2012), which has a prevalence of ~9% in those >65 years old and is a major risk factor for stroke (Piccini et al., 2012; Staerk, Sherer, Ko, Benjamin, & Helm, 2017). In the conduction system, fibrosis causes bradyarrhythmia and heart block, a substantial cause of morbidity in the elderly (Csépe, Kalyanasundaram, Hansen, Zhao, & Fedorov, 2015; Kerola et al., 2019). Risk factors for cardiac fibrosis are diverse and include...
hypertension (Cuspidi, Ciulla, & Zanchetti, 2006), ischaemic heart disease (Hinderer & Schenke-Layland, 2019), aortic stenosis (Bing et al., 2019; Katbeh et al., 2018), inherited cardiomyopathy (Gulati et al., 2013; Ho et al., 2010), diabetes (Russo & Frangogiannis, 2016), and ageing (Lu et al., 2017).

Chronic kidney disease is defined as a persistent loss of renal function and is a growing global health problem, affecting ~13% of the world’s population (Jager & Fraser, 2017). Renal fibrosis occurs in both the glomerulus (glomerulosclerosis) and the tubulointerstitium and is the final common pathway for a diverse range of aetiologies which lead to chronic kidney disease (including infection, ischaemia, diabetes, autoimmune disease, physical obstruction of the urinary tract and toxic or drug insults; Djudjaj & Boor, 2019; Knoppert, Valentijn, Nguyen, Goldschmeding, & Falke, 2019). Fibrosis of the interstitium predicts the progression of chronic kidney disease to end-stage renal failure and may play a role in the transition of acute to chronic renal failure (Hewitson, Holt, & Smith, 2017; Rodríguez-Iturbe, Johnson, & Herrera-Acosta, 2005).

Despite its importance for disease, there are currently no treatments that specifically target cardiac or renal fibrosis. Of note, the majority of cardio-renal fibrotic diseases are more common with increasing age—in particular, chronic kidney disease, diastolic heart failure, atrial fibrillation, aortic stenosis, and cardiac conduction system disease (Figure 1; Chiao, Lakatta, Ungvari, Dai, & Rabinovitch, 2016; O’Sullivan, Hughes, & Ferenbach, 2017). In an increasingly ageing population, the use of effective anti-fibrotic treatments will be important for increasing healthy lifespan.

2 | CELLULAR AND MOLECULAR MECHANISMS OF FIBROSIS

The mechanisms for fibrosis consist of a complex medley of interacting cellular and molecular systems, but a key point of convergence for all forms of fibrosis is the transdifferentiation of fibroblasts into myofibroblasts (Rockey, Bell, & Hill, 2015b; Rosenbloom et al., 2017). Myofibroblasts display two specific features: Firstly, they secrete extracellular matrix which constitutes fibrotic scar (predominantly type I and type III collagen and fibronectin). Secondly, they are contractile—via the expression of α-smooth muscle actin (ACTA2)—thus causing tissue contraction, increased tissue stiffness, and the parenchymal distortion characteristic of fibrotic organs (Rosenbloom et al., 2017; Wynn, 2008).

The molecular factors involved in fibrosis are wide ranging, including PDGF, connective tissue growth factor, angiotensin II and endothelin-1 (Rockey et al., 2015b; Wynn, 2008). But the core pathway, involved in virtually all types of fibrosis, is the TGF-β signalling cascade (Meng, Nikolic-Paterson, & Lan, 2016; Rockey et al., 2015b). However, inhibition of TGF-β—either directly or indirectly—is associated with side effects due to its pleiotropic role across various cell types (Bierie et al., 2009; Shull et al., 1992). Repeated efforts to target TGF-β family members in clinical trials have failed either due to lack of efficacy, likely reflecting dose-limiting toxicities, or due to on-target toxicity itself (Group, C. A. T. Trabeculectomy Study et al., 2007; Voelker et al., 2017). More recently, trials targeting the processing of the latency-associated peptide—as an indirect means of inhibiting TGF-β with suggested less toxicity—were discontinued due to, yet again, safety issues (Keown, 2019).

IL-11 is a less frequently studied cytokine which has only recently been shown to be an important downstream regulator of TGF-β in cardiorenal fibrosis (Schafer et al., 2017). Here, we will suggest that treatments targeting IL-11 have the potential to more safely prevent, treat, and perhaps even reverse fibrotic cardiorenal disease.

3 | IL-11 IS AN IL-6 FAMILY CYTOKINE WITH DISTINCT BIOLOGICAL FUNCTIONS

The IL-6 family of cytokines includes IL-6, IL-11, IL-27, oncostatin M (OSM), leukaemia inhibitory factor (LIF), cardiotoxins-1, 2 and 3.
cardiotrophin-like cytokine (CLCF), and ciliary neurotrophic factor (CNTF; Murakami, Kamimura, & Hirano, 2019; Rose-John, 2018). These cytokines have traditionally been grouped together as they all signal via the ubiquitously expressed signalling receptor subunit glycoprotein 130 kDa (gp130). IL-6 and IL-11 form a complex with a gp130 heterodimer, whereas other members of the family form homodimers (Garbers & Scheller, 2013; Taga & Kishimoto, 1997). This has led to a belief that the functions of some of these cytokines are partly overlapping and redundant. However, specificity is provided by unique, high-affinity receptor subunits leading to a diversity in biological function which is apparent from genetics: mutations affecting the function of the OSM-specific receptor lead to familial primary localized cutaneous amyloidosis (Arita et al., 2008), whereas mutations in the LIF receptor cause Stûve-Wiedemann syndrome, a severe form of bent-bone dysplasia which typically causes death in early life (Dagoneau et al., 2004). Null mutations in CNTF cause motor neuron degeneration in mice (Masu et al., 1993) but do not cause disease in humans (Takahashi et al., 1994). While IL-6 has been very extensively studied, the functions of the other IL-6 family cytokines remain less well understood.

IL-11 is most often compared to IL-6 as both initiate signalling by forming ostensibly similar hexameric complexes with their cognate receptors and gp130. In both cases, the cytokine first binds with its "α" receptor (IL-6RA or IL-11RA) either at the membrane (classical signalling) or, at least for IL-6, in solution (trans-signalling). This complex then interacts with gp130 molecules, triggering their dimerization and subsequent downstream signalling (Garbers & Scheller, 2013; Taga & Kishimoto, 1997). However, important structural differences have been found between IL-6 and IL-11, suggesting that IL-11 may engage gp130 differently to IL-6, with potential consequences for downstream effects (Putočki, Dobson, & Griffin, 2014). Indeed, IL-6 is known to signal predominantly via the JAK/STAT pathway (Taga & Kishimoto, 1997). However, recent work in fibroblasts found that IL-11 causes sustained ERK activation, without physiologically relevant activation of STAT (Ng et al., 2019; Schafer et al., 2017; Widjaja, Sing, et al., 2019). It has also been shown that IL-11 at high concentrations can activate STAT in transformed cell lines (Lu et al., 1994) and some primary cells, although some of these cell lines do not appear to express the IL-11RA, which requires further study.

Importantly, IL-6RA and IL-11RA differ in their expression pattern across cell types, indeed almost exclusively so in the FANTOM datasets, in support of the concept that IL-11 and IL-6 activate distinct target cell populations (Schafer et al., 2017). IL-6RA is most highly expressed on immune cells and as such has become an important target for treating immune-mediated diseases, such as rheumatoid arthritis. IL-6RA has also been detected in transformed hepatic cells such as HepG2. In contrast, IL-11RA is most highly expressed on stromal cells including fibroblasts, vascular smooth muscle cells, adipocytes, hepatic/pancreatic stellate cells, and pericytes, as well as on polarized cells such as hepatocytes, alveolar epithelial cells, and kidney tubular epithelial cells (Ng et al., 2019; Schafer et al., 2017; Widjaja, Sing, et al., 2019).

In keeping with these differences, the effect of loss-of-function mutations in the IL-6 pathway varies greatly from those in the IL-11 pathway. Humans with homozygous loss-of-function mutations in IL-6R suffer from severe immune dysregulation (Spencer et al., 2019), and predicted loss-of-function mutations in IL-6R are selected against in the general population. Accordingly, one of the most frequent on-target side effects of anti-IL-6 therapy is infection (Khanna et al., 2016). In contrast, predicted loss-of-function mutations in IL-11 or IL-11RA in the general population are not selected against and are as common as expected by chance (Karczewski et al., 2019). Individuals with biallelic (homozygous or compound heterozygous) null mutations in IL-11RA sometimes have abnormalities of delayed tooth eruption, mild craniostenosis, scoliosis, and joint laxity but are otherwise healthy, with no increased risk of cancer, wound healing, cardiovascular disease, immune dysfunction or infection (Keupp et al., 2013; Miller et al., 2017; Nieminen et al., 2011; Papachristoforou, Petrou, Sawyer, Williams, & Drousiotou, 2014). It is also notable that while IL-6 is expressed in healthy adults, IL-11 is not, suggesting that IL-11 plays a limited role in healthy adult humans.

4 | DISCOVERY OF IL-11 AND DEVELOPMENT OF RECOMBINANT HUMAN IL-11 TO TREAT THROMBOCYTOPAENIA

IL-11 was initially characterized as a stromal-derived cytokine able to stimulate megakaryocyte colony formation and also to exert an inhibitory action on adipogenesis in the bone marrow micro-environment (Kawashima et al., 1991; Kawashima & Takiguchi, 1992; Keller, Du, Sour, Hoffman, & Williams, 1993; Paul et al., 1990). The initial characterization as a haematopoietic cytokine inspired studies of IL-11 on platelet production, which it was found to increase in vivo. This chance finding led to the development of recombinant human IL-11 (rhl-11) for the treatment of chemotherapy-induced thrombocytopenia (Isaacs et al., 1997).

However, it was later found that IL11ra1 knockout mice and humans with a null mutation in the IL11RA gene display normal blood cell counts (Brischoux-Boucher et al., 2018; Nandurkar et al., 1997), indicating that IL-11 signalling is, in fact, redundant for normal haematopoiesis. IL-11 alone was found in some studies not to directly stimulate megakaryocytes (Teramura, Kobayashi, Hoshino, Oshimi, & Mizoguchi, 1992), and long-term anti-IL-11 therapy in mice has no effect on platelet counts (Widjaja, Singh, et al., 2019). Following its development as a therapeutic agent in the 1990s, rHL-11 became readily available as a tool for the scientific community and was used extensively to study the effects of rhIL-11 in preclinical rodent models. Unfortunately, as we discuss in detail below, recombinant IL-11 has species-specific activity (Schafer et al., 2017; Widjaja, Dong, et al., 2019), and the use of rhIL-11 in mice and rats has led to misunderstanding as to the true biological function of IL-11.
5 | REDISCOVERY OF IL-11 IN HUMAN CARDIAC FIBROBLASTS: A MASTER SWITCH FOR FIBROSIS

As discussed, TGF-β1 is a major driver of fibrosis across organs and disease aetiologies, inducing the transition of fibroblasts into activated myofibroblasts which express ACTA2 and deposit ECM (Akhurst & Hata, 2012; Rockey et al., 2015b). However, the ability to target TGF-β1 to reduce fibrosis is limited by on-target side effects (Bierie et al., 2009; Shull et al., 1992). Therefore, to look for potential drug targets downstream of TGF-β1 with the potential to block fibrosis while avoiding toxicities outside of the fibroblast, Schafer et al. (2017) combined quantification of fibroblast activation and ECM production with RNA sequencing of TGF-β1-stimulated, versus unstimulated, primary human cardiac fibroblast cultures. Unexpectedly, IL-11 up-regulation by more than eightfold was the dominant genome-wide response to human cardiac fibroblast cultures. In contrast to this, in fibroblasts IL-11 was found to drive pro-fibrotic gene expression at the post-transcriptional level, which results in myofibroblast activation and secretion of ECM proteins. This effect appears to be dependent on the phosphorylation of ERK and its downstream targets—increasing 40S ribosomal protein S6 kinase (RSK) and eukaryotic translation initiation factor 4E (eIF4E)—which are involved in activation of protein translation (Schafer et al., 2017). MEK/ERK inhibitors (U0126 and PD98509) block the pro-fibrotic effect of IL-11 on fibroblasts, and TGF-β1 stimulation is unable to activate ERK in fibroblasts isolated from IL-11ra1−/− mice (Ng et al., 2019; Schafer et al., 2017). Interestingly, STAT3—considered the canonical signalling pathway for IL-11—is only mildly and transiently phosphorylated after IL-11 stimulation in primary fibroblasts, and this has little measurable transcriptional consequences. Further insights into IL-11 signalling mechanisms have recently been elucidated by a study suggesting that IL-11 may mediate translation of proline-rich proteins (such as collagen or IL-11 itself) via activation of glutamyl-prolyl-tRNA synthetase (EPRS) (Wu, Subbaiah, Xie, Jiang, & Mickelsen, 2019).

In primary human cardiac fibroblasts, the post-transcriptional gene expression programme dependent on autocrine IL-11 signalling is a necessary requirement for fibrogenesis, downstream of multiple pro-fibrotic stimuli (Figure 2). Previous studies suggest that IL-11 activates myofibroblasts and results in ECM secretion post-transcriptionally via ERK (Figure 3), but other non-canonical pathways may also play a role. It is also unclear whether signalling downstream of IL-11 is different across cell types and states. In addition to stromal cells, many polarized and epithelial cells—such as cardiac myocytes, hepatocytes, alveolar, and tubular epithelial cells—also express IL-11RA and pathways of activation following IL-11 binding may vary.

6 | IL-11 SIGNALS VIA THE ERK PATHWAY IN FIBROBLASTS TO ACTIVATE PRO-FIBROTIC COMPONENTS POST-TRANSCRIPTIONALLY

In contrast to TGF-β, which has profound effects on transcription, RNA-seq data have consistently shown negligible differences in mRNA levels following IL-11 stimulation of fibroblasts (Ng et al., 2019; Schafer et al., 2017). This is somewhat unexpected, as both IL-6 and IL-11 signal via a gp130 homodimer, which results in canonical JAK/STAT activation downstream of IL-6 to initiate a pro-inflammatory RNA expression profile. In contrast to this, in fibroblasts IL-11 was found to drive pro-fibrotic gene expression at the post-transcriptional level, which results in myofibroblast activation and secretion of ECM proteins. This effect appears to be dependent on the phosphorylation of ERK and its downstream targets—including 40S ribosomal protein S6 kinase (RSK) and eukaryotic translation initiation factor 4E (eIF4E)—which are involved in activation of protein translation (Schafer et al., 2017). MEK/ERK inhibitors (U0126 and PD98509) block the pro-fibrotic effect of IL-11 on fibroblasts, and TGF-β1 stimulation is unable to activate ERK in fibroblasts isolated from IL-11ra1−/− mice (Ng et al., 2019; Schafer et al., 2017). Interestingly, STAT3—considered the canonical signalling pathway for IL-11—is only mildly and transiently phosphorylated after IL-11 stimulation in primary fibroblasts, and this has little measurable transcriptional consequences. Further insights into IL-11 signalling mechanisms have recently been elucidated by a study suggesting that IL-11 may mediate translation of proline-rich proteins (such as collagen or IL-11 itself) via activation of glutamyl-prolyl-tRNA synthetase (EPRS) (Wu, Subbaiah, Xie, Jiang, & Mickelsen, 2019).

In primary human cardiac fibroblasts, the post-transcriptional gene expression programme dependent on autocrine IL-11 signalling is a necessary requirement for fibrogenesis, downstream of multiple pro-fibrotic stimuli (Figure 2). Previous studies suggest that IL-11 activates myofibroblasts and results in ECM secretion post-transcriptionally via ERK (Figure 3), but other non-canonical pathways may also play a role. It is also unclear whether signalling downstream of IL-11 is different across cell types and states. In addition to stromal cells, many polarized and epithelial cells—such as cardiac myocytes, hepatocytes, alveolar, and tubular epithelial cells—also express IL-11RA and pathways of activation following IL-11 binding may vary.

7 | ROLE OF IL-11 IN EPITHELIAL VERSUS STROMAL CELLS

In this review, we concentrate mainly on the pro-fibrotic role of IL-11 in stromal cells (fibroblasts). However, it should be noted that there is evidence of IL-11 release from and signalling within epithelial cells, typically in response to acute injury. For example, respiratory syncytial virus is a potent stimulus for IL-11 secretion from lung epithelium (Einarsson, Geba, Zhu, Landry, & Elias, 1996; Elias et al., 1994). Similarly, IL-11 is released from hepatocytes after injury with paracetamol.
(acetaminophen) and can then act in an autocrine manner to induce ROS and cell death (Widjaja, Dong, et al., 2019). In epithelial cells isolated from lung organoid models of idiopathic pulmonary fibrosis, IL-11 expression is increased and is hypothesized to have a role in epithelial-to-mesenchymal transition and the early initiation of fibrosis (Strikoudis et al., 2019). In the kidney, the response of tubular epithelial cells to injury are now thought to have a crucial role in the initiation of fibrosis and the transition from acute to chronic renal failure (Qi & Yang, 2018). Given the large and relatively early increases in IL-11 expression observed in whole kidney tissue following injury (Table 1 and discussed below), there may be an important role for IL-11 signalling in tubular epithelial cells. Exploring this should be a priority for future study.

8 | IL-11 IS ASSOCIATED WITH FIBROTIC CARDIOVASCULAR DISEASE IN MOUSE MODELS AND HUMAN PATIENTS

In the heart, IL-11RA is expressed on both fibroblasts and cardiomyocytes (Kimura et al., 2007; FANTOM Consortium and the RIKEN PMI and CLST [DGT] et al., 2014). As mentioned, the dominant transcriptional response to TGF-β stimulation of human atrial fibroblasts is IL-11 expression (Schafer et al., 2017). Several studies have explored the association of IL-11 and cardiovascular disease across species. These are summarized in Table 1 and discussed below.

Following myocardial infarction in mice, IL-11 expression is up-regulated >50-fold after 24 hr, and increased levels are maintained for at least 14 days (Obana et al., 2010). Similarly, in rats fed a high-salt diet—resulting in hypertension, cardiac fibrosis, and heart failure with preserved ejection fraction—cardiac IL-11 expression is significantly increased (Zhou et al., 2019). In two other models of fibrotic heart disease—continuous angiotensin II infusion and transverse aortic constriction—increased levels of IL-11 protein are seen in the heart (Schafer et al., 2017).

In humans, serum IL-11 is increased in patients with congestive cardiac failure, correlates with the severity of heart failure symptoms, and predicts cardiac events including cardiovascular death and heart failure rehospitalization (Ye et al., 2019). Similarly, serum IL-11 is raised in patients with coronary heart disease (Liu et al., 2015), and both serum and aortic IL-11 are increased in patients with thoracic aortic dissection (Xu et al., 2018). Intriguingly, common side effects of rhIL-11 in patients being treated for thrombocytopenia include atrial arrhythmia, pulmonary congestion, raised brain natriuretic peptide levels, and, in some cases, left ventricular failure (Liu et al., 2019; Smith, 2000), though this is at least partly related to acute sodium and water retention (Dykstra et al., 2000).

In summary, increased IL-11 levels are found in primary human cells subjected to pro-fibrotic stimuli, in the hearts of mice with fibrotic heart disease and in the serum and tissue of patients with cardiovascular disease. These associations suggest that IL-11 may have a pathogenic role in fibrotic cardiac disease. An alternative explanation—which is prevalent in the literature—is that IL-11 is protective against fibrotic heart disease and is induced as a natural suppressor of fibrosis. In the next section, we discuss how earlier work studying the effect of recombinant human IL-11 (rhIL-11) on the mouse or rat heart suggested the latter conclusion, whereas more recent work using species-matched IL-11 has revealed the true pathological role of IL-11 as a pro-fibrotic cytokine.

9 | SPECIES-SPECIFIC RECOMBINANT IL-11 HAS A PRO-FIBROTIC EFFECT ON THE HEART

In 2007, Kimura et al. reported that pretreatment with an IL-11 infusion had a protective and anti-fibrotic effect in mice subjected to 60 min of cardiac ischaemia followed by reperfusion. Subsequent work found similar results in permanent left coronary artery ligation (Obana et al., 2010), in post-reperfusion treatment (Obana et al., 2012) and in a cold
| Reference                  | Species                  | Experimental design                                                                 | Findings related to IL-11                                                                 | Study used recombinant human IL-11 in a rodent model |
|----------------------------|--------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Menendez-Castro et al., 2019 | Rats, strain unspecified | Renovascular hypertension was induced by clipping of one renal artery (1 clip, 2 kidney model). The kidney of rats developing malignant hypertensive nephrosclerosis were compared with those of rats which were hypertensive but did not develop malignant nephrosclerosis. Control animals received a sham operation. | IL-11 mRNA was up-regulated 28.3-fold in the kidneys of rats with malignant hypertension and 11.9-fold in non-malignant hypertension. This was confirmed at the protein level by Western blot. IL-11 expression correlated with collagen deposition, myofibroblast activation and with TGF-ß1, TIMP-1, and Col1a expression. | NA                                                   |
| Bigaeva et al., 2019       | Humans and mice (C57BL/6) | Cultured precision cut tissue slices (PCTS) were prepared from the explanted kidneys of healthy mice, healthy humans and diseased humans. RNA-seq compared the transcriptomic response after 48 hr of culture (by which time pro-fibrotic changes have occurred) to that pre-culture. | IL-11 was one of the few genes strongly up-regulated in cultured kidney PCTS across species and disease states (5 to 10-fold increase). | NA                                                   |
| Harlan et al., 2018        | Mice, C57BKLS db/db      | Chronic kidney disease was induced by the combined effects of hypertension (AAV-mediated renin expression plus uni-nephrectomy) and Type 2 diabetes (db/db mouse). | Microarray analysis showed significant up-regulation of IL-11 expression in mice with chronic kidney disease. | NA                                                   |
| Schafer et al., 2017       | Mice, C57BL/6J background | Kidney injury induced by a single i.p. injection of folic acid (FA) 180 mg·kg⁻¹ in wild-type or IL-11ra1 KO mice; kidneys assessed at Day 28 | Kidney injury from FA resulted in expression of IL-11 protein and significant renal fibrosis in wild-type mice. IL-11ra1 KO prevented FA-induced kidney fibrosis. | NA                                                   |
| Grgic et al., 2014         | Mice, C57BL/6J background | Time course of IL-11 mRNA levels assessed in two models: Model 1: UUO for up to 5 days. Model 2: 35 min of unilateral IRI (UIRI) for up to 28 days | In UUO, IL-11 expression was up-regulated 80-fold by 48 hr and remained elevated at 20-fold up to experiment conclusion at Day 5. In UIRI, IL-11 expression was >200-fold up-regulated by 24 hr, remaining elevated to at least Day 28. | NA                                                   |
| Xu, Podok, Xie, & Lu, 2014 | Crucian carp             | Carp were infected with Cyprinid herpesvirus 2. Virus specific host gene activation in the head kidneys of the carp was assessed in moribund versus surviving fish. The kidney is a principal immune organ of the fish. | IL11 is the most highly expressed gene in the head kidney of moribund versus surviving fish, being up-regulated 200-fold. | NA                                                   |
| Kim et al., 2013           | Mice, C57BL/6 background | Mice were subjected to 20 or 30 min unilateral IRI with contralateral nephrectomy. The effect of a selective adenosine A₁ receptor agonist (CCPA) on renal injury was assessed in wild-type | 1. Administration of a selective A₁ adenosine receptor agonist CCPA induces IL-11 in mouse kidneys | NA                                                   |
| Reference | Species | Experimental design | Findings related to IL-11 | Study used recombinant human IL-11 in a rodent model |
|-----------|---------|---------------------|---------------------------|---------------------------------------------------|
| Mitazaki, Kato, Suto, Hiraïwa, & Abe, 2009 | Mice, C57BL/6J | Acute renal failure was induced by a single high-dose injection of cisplatin 30 mg kg⁻¹ i.p. | IL-11 expression is up-regulated ~80-fold at 72 hr after cisplatin injection | NA |
| Chien et al., 2006 | Humans | 24-hr urine collected from patients with IgA nephropathy, lupus nephritis, or idiopathic nephrotic syndrome and assessed for total protein, IL-11 protein, and IL-11 mRNA. | Urinary IL-11 protein and urinary IL-11 mRNA significantly correlated with total proteinuria in patients with IgA nephropathy and lupus nephritis. | NA |
| Lemay, Rabb, Postler, & Singh, 2000 | Mice, NIH Swiss | Mice underwent 30-min bilateral IRI. Kidneys were harvested at 1, 4, 12 or 24 hr after ischaemia. | IL-11 mRNA was raised at 4, 12, and 24 hr, with the peak at 12 hr | NA |
| Schafer et al., 2017 | Mice, C57BL/6J background | Exp 1: Recombinant mouse IL-11 (rmIL-11) injected (100 μg kg⁻¹ day⁻¹, 3 weeks) into Col1a-GFP reporter mouse. Exp 2: Inducible rmIL-11 mouse created by crossing rmIL-11-Tg mice with Col1a2-Cre mice. | Both exogenous rmIL-11 injection and induced rmIL-11 expression produced activation of fibroblasts in the renal interstitium, caused renal fibrosis and impaired renal function. | X |
| Lee et al., 2012 | Mice, C57BL/6 background | Mice underwent 30+min unilateral IRI with contralateral nephrectomy. Recombinant human IL-11 or vehicle was given, either pre- or 30–60 min post-IRI. | Mice receiving rhIL-11 had lower serum creatinine and reduced renal apoptosis, necrosis, and inflammation. | ✓ |
| Lai et al., 2005 | Mice, C57BL/6J | Recombinant human IL-11 injected in a mouse model of crescentic glomerulonephritis induced by injection of sheep anti-mouse nephrotoxic serum | Human IL-11 treatment decreased albuminuria, glomerular macrophage number, and glomerular fibrin deposition in mice | ✓ |
| Lai et al., 2001 | Rats, Wistar Kyoto | Recombinant human IL-11 injected in a rat model of necrotizing glomerulonephritis induced by an injection of anti-glomerular basement membrane antibody | Human IL-11 reduced proteinuria, fibrinoid necrosis, and macrophage activation in rats | ✓ |
| Ye et al., 2019 | Humans | Plasma concentrations of IL-11 were measured in 240 patients with chronic heart failure and compared to 80 patients without signs of heart disease. Patients were followed up for the occurrence of cardiac events. | Plasma IL-11 level was ~1.3-fold higher in the heart failure patients than in the control group. In patients, IL-11 levels correlated with symptoms, with NT-pro BNP level and predicted cardiac events. | NA |
| Xu et al., 2018 | Humans | Aortic tissue samples were collected from patients with acute thoracic aortic dissection. Blood samples | IL-11 was increased greater than twofold in the aortic tissue of | NA |

(Relates to)
**TABLE 1**

| Reference | Species | Experimental design | Findings related to IL-11 | Study used recombinant human IL-11 in a rodent model |
|-----------|---------|---------------------|---------------------------|---------------------------------------------------|
| Liu et al., 2015 | Humans | Serum cytokine levels were assessed in patients undergoing invasive coronary angiography: patients found to have coronary artery disease were compared to those completely free of coronary atherosclerosis | Serum IL-11 was significantly higher in patients with coronary artery disease compared to those without. However, IL-11 level did not correlate with the degree of coronary disease assessed by Gensini score. | NA |
| Smith, 2000 | Humans | Review of safety data from randomized trials in patients receiving rhIL-11 for treatment of chemotherapy-induced thrombocytopenia. | Common side effects of rhIL-11 in human cancer patients include oedema, dyspnoea, pleural effusions, and atrial arrhythmia. | NA |
| Liu et al., 2019 | Humans | The cardiovascular side effects of rhIL-11 were assessed in 24 leukaemia patients receiving rhIL-11 for treatment of chemotherapy-induced thrombocytopenia. | During rhIL-11 treatment, patients’ brain natriuretic peptide levels rose from 22 to 215 pg ml⁻¹. 38% of patients had oedema and weight gain. 17% experienced acute left ventricular failure. 8% had an episode of paroxysmal atrial fibrillation. | X |
| Tamura, Kohno, Mohri, Fujio, & Matsumiya, 2018 | Rats, Sprague-Dawley | Recombinant human IL-11 was given i.v. 10 min before harvesting the rat heart. The hearts were preserved in cold buffer for 6 hr before being reperfused with solution containing either rhIL-11 or saline. | rhIL-11 improved myocardial function (LV developed pressure and change in LV pressure) after 6 hr of cold ischaemia. The number of apoptotic cardiomyocytes was also reduced approximately fourfold. | ✓ |
| Schafer et al., 2017 | Mice, C57BL/6J background | Exp 1: Recombinant mouse IL-11 (rmIL-11, 100 μg kg⁻¹ day⁻¹) or PBS was administered to mice for 6 days following ligation of the left coronary artery. Exp 2: Inducible rmIL-11 mouse created by crossing rmIL-11-Tg mice with Col1a2-Cre mice. | Exogenous or induced rmIL-11 resulted in greater epicardial fibrosis and worse cardiac function after myocardial infarction. In addition, while rmIL-11 activated mouse cardiac fibroblasts in vitro (EC⁵₀, 2 ng ml⁻¹), rhIL-11 did not activate mouse cardiac fibroblasts | X |
| Obana et al., 2012 | Mice, C57BL/6 | Mice received 30 min of cardiac ischaemia followed by 24-hr reperfusion. Recombinant human rhIL-11 reduced myocardial damage 1.6-fold, reduced myocardial | | ✓ |

(Continues)
ischaemia model designed to mimic the conditions of cardiac transplant (Tamura et al., 2018). However, in all cases, mice or rats received recombinant human—rather than mouse or rat—IL-11 at high doses.

These earlier data directly contrast the more recent results discussed in the previous section, which showed a strong pro-fibrotic effect of recombinant human IL-11 when applied to primary human myofibroblasts (Schafer et al., 2017). To explore this apparent contra-effect of recombinant human IL-11 on mouse fibroblasts during the in vitro experiments demonstrated that rhIL-11 binds to the mouse IL-11ra1 with a slightly higher affinity than rmIL-11. Competition ELISA showed that rhIL-11 is a highly effective blocker of mouse IL-11 binding to IL-11ra1 and that rhIL-11 actually inhibits rmIL-11 activity in murine hepatocytes. Thus—paradoxically—rhIL-11 acts as an inhibitor of endogenous IL-11 in mice, a result which may explain the protective effect of rhIL-11 in rodent models of IL-11-mediated disease (Widjaja, Dong, et al., 2019).

Expanding on the in vitro results, Schafer et al. (2017) tested the effect of injecting recombinant mouse IL-11 into healthy mice. In contrast to the earlier studies that had used human IL-11 in the mouse, this resulted in cardiac and renal fibrosis. Injection of rmIL-11 to the mouse increased epicardial fibroblast activation, a hallmark of fibrosis in myocardial infarction, and resulted in worsening of left ventricular function (Schafer et al., 2017).

Next, the in vivo effects of fibroblast-specific IL-11 expression were investigated by generating murine Il11-transgenic mice crossed with Tam-inducible Col1a2 −/−Cre mice: Within 2 weeks, there was widespread activation of cardiac and renal fibroblasts and accumulation of collagen. This was accompanied by a reduction in cardiac and renal function and increased serum TGF-β1 (Schafer et al., 2017).

Together, these results show that IL-11 biology is conserved across species, but the role of endogenous IL-11 cannot be inferred from the use of recombinant human IL-11 on rodent cells or tissues. The effect of species-matched IL-11, either administered exogenously or overexpressed endogenously, is pro-fibrotic in the heart. Combined

**TABLE 1** (Continued)

| Reference | Species | Experimental design | Findings related to IL-11 | Study used recombinant human IL-11 in a rodent model |
|-----------|---------|---------------------|--------------------------|-----------------------------------------------|
| Obana et al., 2010 | Mice, C57BL/6 | Myocardial infarction (MI) was induced by ligation of the left coronary artery. Recombinant human IL-11 (8 μg kg⁻¹, i.v.) was administered daily for 5 days by i.v. Mouse hearts were harvested at 14 days. IL-11 mRNA was up-regulated >50-fold in the infarct zone, and 20-fold in the remote zone, 24 hr after MI, maintained for ≥7 days. Intravenous rhIL-11 up-regulated p-STAT3 in explanted mouse myocardium, reduced infarct area by 33%, reduced cardiomyocyte apoptosis, and improved LV function. ✓ |
| Kimura et al., 2007 | Mice, C57BL/6 | Recombinant human IL-11 (8 μg kg⁻¹) or PBS was injected into mice 15 hr before cardiac IRI was induced via 60-min left coronary artery ligation. Hearts were harvested after 60 min of reperfusion. Cultured rat cardiomyocytes were stimulated with rhIL-11 | rhIL-11 reduced infarct size by 63%. In vitro, high-dose rhIL-11 (20 ng ml⁻¹) activated STAT3 and ERK in rat cultured cardiomyocytes. ✓ |

Abbreviations: AAV, adeno-assocaied virus; BNP, brain (or b-type) natriuretic peptide; CCPA, 2-chloro-N⁶-cyclopentyladenosine; Col1a, collagen type I α; FA, folic acid; IL-11ra1: IL-11 receptor subunit α; IRI, ischaemia reperfusion injury; KO, knock out; LV, left ventricle; MI, myocardial infarction; NT-pro BNP, N-terminal pro b-type natriuretic peptide; PCTS, precision cut tissue slices; p-STAT3, phosphorylated STAT3; rhIL-11, recombinant human IL-11; rmIL-11, recombinant mouse IL-11; Tg, transgenic; TIMP1, metallopeptidase inhibitor 1; UUO: unilateral ureteric obstruction.
with the observational data of increased IL-11 in multiple animal models and human cardiac disease, this suggests a causative role for IL-11 in fibrinoid heart disease, rather than the previously assumed protective, anti-inflammatory, and anti-fibrotic role.

10 | IL-11 IS ASSOCIATED WITH RENAL INJURY IN DIVERSE ANIMAL MODELS AND IN HUMAN PATIENTS

Fibrotic renal injury in patients can result from diverse insults. Experiments with animal models across different species (mouse, rat, and carp) have found an association between IL-11 and the varied renal insults, including ischemia (Grgic et al., 2014; Lemay et al., 2000), drug or chemical toxicity (Mitazaki et al., 2009; Schafer et al., 2017), hypertension (Harlan et al., 2018; Menendez-Castro et al., 2019), diabetes (Harlan et al., 2018), infection (Xu et al., 2014), and physical obstruction of the urinary tract (Grgic et al., 2014). These studies are summarized in Table 1.

In humans, few studies to date have investigated the role of IL-11 in renal disease. However, a study in paediatric patients found a highly significant correlation between urinary IL-11 protein and mRNA levels and proteinuria in patients with IgA nephropathy or lupus nephritis (Chien et al., 2006). In primary human renal epithelial cells, adenovirus-mediated expression of GADD45γ (a protein highly up-regulated in renal tissue injured by urinary tract obstruction) results in a 6.7-fold up-regulation of IL-11 expression (Shin, Kim, Lim, Yim, & Kim, 2008). A recent study by Bigaeva et al. (2019) used RNA-seq in cultured precision cut tissue slices (PCTS)—an in vitro model of fibrosis which maintains the complex three-dimensional structures of organs—to assess the fibrosis-associated transcriptomic response in healthy mouse, healthy human, and diseased human tissues. They found that IL-11 was one of the few genes to be consistently up-regulated in PCTS across species and organs (including kidney, liver, ileum, and colon; cardiac tissue was not assessed). In particular, IL-11 was one of the most up-regulated genes (5- to 10-fold) in kidney PCTS from healthy mouse, healthy human, and diseased human (end-stage renal failure) donors.

11 | SPECIES-MATCHED EXOGENOUS IL-11 CAUSES KIDNEY FIBROSIS AND DYSFUNCTION

Similar to work on cardiac fibrosis, the role of IL-11 in kidney disease has likely been confounded and confused by the use of recombinant human IL-11 (rhIL-11) in rodent models. For example, it has been shown that rhIL-11 protects from renal-ischaemia reperfusion injury (Lee et al., 2012) and suppresses extracellular matrix deposition and glomerular injury in experimental glomerulonephritis (Lai et al., 2001, 2005).

In contrast, more recent work has shown that exogenous administration or overexpression of mouse IL-11 in the mouse causes, rather than inhibits, renal fibrosis. Three weeks of daily rmIL-11 treatment in mice activated fibroblasts in the renal interstitium, resulted in deposition of collagen and caused impairment of renal function (Schafer et al., 2017). Similarly, 2 weeks of inducible IL-11 overexpression in a fibroblast-specific manner in murine Il11-transgenic mice crossed with inducible Col1a2−/Cre mice caused renal fibrosis and an increase in serum urea and creatinine, indicating renal dysfunction (Schafer et al., 2017).

12 | GENETIC DELETION OF THE IL-11 RECEPTOR HAS NO MAJOR ADVERSE EFFECTS AND PROTECTS AGAINST CARDIAC AND RENAL FIBROSIS IN MICE

Individuals with biallelic null mutations in IL-11RA have delayed tooth eruption, mild craniosynostosis, and variable joint laxity but are otherwise well (Brischoux-Boucher et al., 2018; Keupp et al., 2013; Nieminen et al., 2011). IL-11ra1−/− mice are a notable phenocopy of the human null phenotype, having slight developmental abnormalities of the skull and teeth but being otherwise healthy with a normal lifespan, although females (unlike human female nulls) are infertile (Nandurkar et al., 1997).

The similarities in the human and mouse IL-11RA null phenotype suggest strong conservation of IL-11 function across mammalian species and that proof-of-concept studies targeting IL-11 in mice could provide valuable data that translate to humans. Furthermore, the lack of overt adverse post-developmental consequences of IL-11RA deletion in either mice or humans suggests that targeting IL-11 signalling could be a safe means to treat fibrosis in adult mammals.

To investigate this further, IL-11ra1−/− mice were compared to wild-type controls in three independent models of cardiac and renal fibrosis (Schafer et al., 2017). Following angiotensin II infusion or transverse aortic constriction, IL-11ra1−/− mice had less cardiac fibrosis than wild-type mice, an effect which was independent of loading conditions. Similarly, after folic acid-induced kidney injury, IL-11ra1−/− mice had reduced renal fibrosis. Deletion of IL-11ra1 signalling resulted in reduced ERK signalling across all models tested.

13 | NEUTRALIZING IL-11 ANTIBODIES ARE ANTI-FIBROTIC

Our group genetically immunized mice with IL-11 to generate neutralizing IL-11 antibodies. Clones were then screened for neutralization activity using fibroblast transformation as a readout. Clones X203 (anti-IL-11) and X209 (anti-IL-11ra1) effectively blocked the fibrotic response in mice and human cells and were chosen for preclinical testing in mouse models (Ng et al., 2019; Widjaja, Singh, et al., 2019). Neutralizing anti-IL-11 antibodies markedly reduced the pro-fibrotic effect of TGF-β stimulation on atrial fibroblasts across a wide range of assays, including myofibroblast activation, ECM production, and gel contraction and cell migration (Ng et al., 2019; Schafer et al., 2017).
In animal models, clones X203 and/or X209 have been shown to prevent or reverse fibrosis in the lung and liver (Ng et al., 2019; Widjaja, Singh, et al., 2019). Studies investigating the effects of anti-IL-11 therapy on cardiac or renal fibrosis are ongoing and are expected to be reported in the near future.

14 | CONCLUSIONS

Fibrosis is a key and common driver of cardiac and renal failure, which account for a large proportion of global morbidity and mortality. As fibrotic diseases are more prevalent in older individuals, this burden will increase as populations age. Therefore, new treatments that safely and specifically target cardiorenal fibrosis are needed, and this represents an unmet medical need. This is especially so, given that recent trials have now clearly shown that targeting TGF-β directly, or indirectly via integrins, is toxic and ineffective and new drug targets are needed.

IL-11 up-regulation—acting downstream of TGF-β and other pro-fibrotic factors—appears to be a unifying feature underlying cardio-renal fibrotic diseases. Earlier work using human IL-11 in murine models led to the conclusion that its up-regulation in fibroinflammatory diseases was a protective response, a compensatory mechanism to prevent runaway fibrosis. More recent studies have questioned this conclusion: The true endogenous role of IL-11 appears pro-fibrotic, resulting in the activation of myofibroblasts, inflammation, the deposition of ECM and ultimately organ dysfunction and failure.

From a therapeutic point of view, biallelic IL-11RA null mutations in mice and humans are tolerated in adults, which suggests inhibiting IL-11 signalling may be safe, but this remains to be proven. Future work exploring the effect of anti-IL-11 therapies in animal models and, ultimately, in human clinical trials will determine if its potential can be realized to help the millions of patients worldwide suffering with fibrotic diseases of the kidney or heart.

14.1 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander, Fabbro et al., 2019a, b; Alexander, Kelly et al., 2019).

CONFLICT OF INTEREST

S.A.C. and S.S. are co-inventors of the patent applications (WO/2017/103108: TREATMENT OF FIBROSIS, WO/2018/109174: IL-11 ANTIBODIES, WO/2018/109170: IL-11RA ANTIBODIES). S.A.C. and S.S. are co-founders and shareholders of Enleofen Bio PTE LTD, a company that develops anti-IL-11 therapeutics.

REFERENCES

Akhurst, R. J., & Hata, A. (2012). Targeting the TGFβ signalling pathway in disease. Nature Reviews. Drug Discovery, 11, 790–811. https://doi.org/10.1038/nrd3810
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., ... CGTP Collaborators (2019a). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors. British Journal of Pharmacology, 176, S247–S296. https://doi.org/10.1111/bph.14751
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., ... CGTP Collaborators (2019b). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297–S396. https://doi.org/10.1111/bph.14752
Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Faccenda, E., ... CGTP Collaborators (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. British Journal of Pharmacology, 176, S1–S20. https://doi.org/10.1111/bph.14747
Arita, K., South, A. P., Hans-Filho, G., Sakuma, T. H., Lai-Cheong, J., Clements, S., ... McGrath, J. (2008). Oncostatin M receptor-β mutations underlie familial primary localized cutaneous amyloidosis. American Journal of Human Genetics, 82, 73–80. https://doi.org/10.1016/j.ajhg.2007.09.002
Bierie, B., Chung, C. H., Parker, J. S., Stover, D. G., Cheng, N., Chytli, A., ... Moses, H. L. (2009). Abrogation of TGF-β signaling enhances chemokine production and correlates with prognosis in human breast cancer. The Journal of Clinical Investigation, 119, 1571–1582. https://doi.org/10.1172/JCI37480
Bigaeva, E., Gore, E., Simon, E., Zwick, M., Oldenburger, A., de Jong, K. P., ... Olinga, P. (2019). Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. Archives of Toxicology, 93, 3549–3583. https://doi.org/10.1007/s00204-019-02611-6
Bing, R., Cavalcante, J. L., Everett, R. J., Clavel, M.-A., Newby, D. E., & Dweck, M. R. (2019). Imaging and impact of myocardial fibrosis in aortic stenosis. JACC: Cardiovascular Imaging, 12, 283–296.
Brischoux-Boucher, E., Trimouille, A., Baujat, G., Goldenberg, A., Schaefer, E., Guichard, B., ... van Maldergem, L. (2018). IL11RA-related Crouzon-like autosomal recessive craniosynostosis in 10 new patients: Resemblances and differences. Clinical Genetics, 94, 373–380. https://doi.org/10.1111/cge.13409
Chen, Z., Sohal, M., Voigt, T., Sammut, E., Tobon-Gomez, C., Child, N., ... Rinaldi, C. A. (2015). Myocardial tissue characterization by cardiac magnetic resonance imaging using T1 mapping predicts ventricular arrhythmia in ischemic and non-ischemic cardiomyopathy patients with implantable cardioverter-defibrillators. Heart Rhythm, 12, 792–801. https://doi.org/10.1016/j.hrthm.2014.12.020
Chiao, Y. A., Lakatta, E., Ungvary, Z., Dai, D.-F., & Rabinoivitch, P. (2016). Cardiovascular disease and aging. In F. Sierra, & R. Kohanski (Eds.), Advances in Geroscience (pp. 121–160). Cham: Springer International Publishing.
Chien, J.-W., Chen, W.-L., Tsui, Y.-G., Lee, M.-C., Lin, A.-Y., & Lin, C.-Y. (2006). Daily urinary interleukin-11 excretion correlated with proteinuria in IgA nephropathy and lupus nephritis. Pediatric Nephrology, 21, 490–496. https://doi.org/10.1007/s00467-006-0016-7
Csepe, T. A., Kalyanasundaram, A., Hansen, B. J., Zhao, J., & Fedorov, V. V. (2015). Fibrosis: A structural modulator of sinoatrial node physiology and dysfunction. Frontiers in Physiology, 6, 37–47.
Cuspidi, C., Ciulla, M., & Zanchetti, A. (2006). Hypertensive myocardial fibrosis. Nephrology, Dialysis, Transplantation, 21, 20–23.
Dagoneau, N., Scheffer, D., Huber, C., Al-Gazali, L. I., Di Rocco, M., Godard, A., ... Nicole, S. (2004). Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. American Journal of Human Genetics, 74, 298–305. https://doi.org/10.1086/381715
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015a). Fibrosis—A common pathway to organ injury and failure. The New England Journal of Medicine, 372, 1138–1149. https://doi.org/10.1056/NEJMra1300575

Rockey, D. C., Bell, P. D., & Hill, J. A. (2015b). Fibrosis—A common pathway to organ injury and failure. The New England Journal of Medicine, 373, 96.

Rodriguez-Iturbe, B., Johnson, R. J., & Herrera-Acosta, J. (2005). Tubulointerstitial damage and progression of renal failure. Kidney International. Supplement, 68, S82–S86. https://doi.org/10.1111/j.1523-1755.2005.00991.x

Rose-John, S. (2018). Interleukin-6 family cytokines. Annual Review of Immunology, 36, 373–419. https://doi.org/10.1146/annurev-immunol-050316-034822

Schafer, S., Viswanathan, S., Wildja, A. A., Lim, W.-W., Moreno-Moral, A., DeLaughter, D. M., & Cook, S. A. (2017). IL-11 is a crucial determinant of cardiovascular fibrosis. Nature, 552, 110–115. https://doi.org/10.1038/nature24676

Shin, G.-T., Kim, D. R., Lim, J.-E., Yim, H., & Kim, H. (2008). Upregulation of TGF-β1 gene results in multifocal inflammatory disease. Journal of Korean Medical Science, 23, 1299–1304. https://doi.org/10.4103/1983-1729.47076

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., & Calvin, D. (1992). Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature, 359, 693–699. https://doi.org/10.1038/359693a0

Smith, J. W. 2nd (2000). Tolerability and side-effect profile of rhlL-11. Oncology, 14, 41–47.

Spencer, S., Köstel Bal, S., Egner, W., Lango Allen, H., Raza, S. I., Ma, C. A., ... Thaventhiran, J. E. D. (2019). Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. The Journal of Experimental Medicine, 216, 1986–1998. https://doi.org/10.1084/jem.20190344

Staerk, L., Shener, J. A., Ko, D., Benjamin, E. J., & Helm, R. H. (2017). Atrial fibrillation: Epidemiology, pathophysiology, and clinical outcomes. Circulation Research, 120, 1501–1517. https://doi.org/10.1161/CIRCRESAHA.117.309732

Strikoudis, A., Cieslak, A., Loffredo, L., Chen, Y.-W., Patel, N., Saqi, A., ... Snoeck, H. W. (2019). Modeling of fibrotic lung disease using 3D organoids derived from human pluripotent stem cells. Cell Reports, 27, 3709, e5–3723. https://doi.org/10.1016/j.celrep.2019.05.077

Taga, T., & Kishimoto, T. (1997). Gp130 and the interleukin-6 family of cytokines. Annual Review of Immunology, 15, 797–819.

Takahashi, R., Yokoji, H., Misawa, H., Hayashi, M., Hu, J., & Deguchi, T. (1994). A null mutation in the human CNTF gene is not causally related to neurological diseases. Nature Genetics, 7, 79–84. https://doi.org/10.1038/ng0594-79

Tamura, Y., Kohno, H., Mohri, T., Fujio, Y., & Matsumiya, G. (2018). The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model. Ann Cardiothorac Surg, 7, 99–105.

Teramura, M., Kobayashi, S., Hoshino, S., Oshimi, K., & Mizoguchi, H. (1992). Interleukin-11 enhances human megakaryocytopenosis in vitro. Blood, 79, 327–331.

Voolker, J., Berg, P. H., Sheetz, M., Duffin, K., Shen, T., Moser, B., ... Lewis, J. B. (2017). Anti-TGF-β1 antibody therapy in patients with diabetic nephropathy. Journal of the American Society of Nephrology, 28, 953–962. https://doi.org/10.1681/ASN.2015111230

Widjaja, A. J., Dong, J., Adami, E., Viswanathan, S., Ng, B., Singh, B. K., ... Tan, J. (2019). Redefining Interleukin 11 as a regeneration-limiting hepatotoxin. bioRxiv. 830018

Widjaja, A. J., Singh, B. K., Adami, E., Viswanathan, S., Dong, J., D’Agostino, G. A., ... Tripathi, M. (2019). Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology, 157, 777, e14–792.

Wu, J., Subbahal, K. C. V., Xie, L. H., Jiang, F., & Mickelsen, D. (2019). EPRS regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. bioRxiv. 82931623.

Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. The Journal of Pathology, 214, 199–210.

Xu, L., Podok, P., Xie, J., & Lu, L. (2014). Comparative analysis of differential gene expression in kidney tissues of moribund and surviving crucian carp (Carassius auratus gibelio) in response to cyprinid herpesvirus 2 infection. Archives of Virology, 159, 1961–1974.

Xu, Y., Ye, J., Wang, M., Wang, Y., Ji, Q., Huang, Y., ... Wan, J. (2018). Increased interleukin-11 levels in thoracic aorta and plasma from patients with acute thoracic aortic dissection. Clinica Chimica Acta, 481, 193–199. https://doi.org/10.1016/j.cca.2018.03.014

Ye, J., Wang, Z., Ye, D., Wang, Y., Wang, M., Ji, Q., ... Wan, J. (2018). Increased interleukin-11 levels are correlated with cardiac events in patients with chronic heart failure. Mediators of Inflammation, 2019;575410, 1–8. https://doi.org/10.1155/2019/1575410

Zhou, L., Filiberti, A., Humphrey, M. B., Fleming, C. D., Scherlag, B. J., Po, S. S., & Stavvakis, S. (2019). Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction. Experimental Physiology, 104, 28–38. https://doi.org/10.1113/EP087351

How to cite this article: Corden B, Adami E, Sweeney M, Schafer S, Cook SA. IL-11 in cardiac and renal fibrosis: Late to the party but a central player. Br J Pharmacol. 2020;177: 1695–1708. https://doi.org/10.1111/bph.15013